Primary open angle glaucoma or ocular hypertension
Conditions
Interventions
Subjects are treated with tafluprost ophthalmic solution once daily for 12 week
Subjects are treated with travoprost ophthalmic solution once daily for 12 week
Sponsors
Hiroshima uiversity
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients who diagnosed with primary open angle glaucoma or ocular hypertension in one eye or both eyes. 2. Patients who has been treated with prostaglandin analogue, adrenergic antagonist or both over 12 weeks or those who is newly diagnosed with primary open angle glaucoma or ocular hypertension. 3. Regardless of sex. 4. Aged 20 years or more. 5. Outpatients. 6. Have provided a written informed consent. 7. In unilateral patient, the affected eye is evaluation eye. In case of bilateral patinet, right eye is evaluation eye.
Exclusion criteria
Exclusion criteria: 1. Patinets who with a history of allergy (i.e. hypersensitivity) to the drugs to be used during the study period. 2. Females who are pregnant, nursing or planning a pregnancy, or females of childbearing potential. 3. Patients who with a history of corneal refractive surgery. 4. Patinets who need wearing contact lenses during the study period. 5. Patinets who with extraocular disease, inflammation or infection in the eye(s) or eyelid(s). 6. Patinets who with a history of cataract surgery within 12 months. 7. Patinets who with a history of intraocular surgery including ocular laser treatment against glaucoma within 12 months 8. Patinets who has been treated with prostaglandin/timolol malate fixed combination. 9. Patinets who has been treated with prostaglandin generic drug. 10. Patinets who is treated dry eye therapy (drug medication, punctum plug and punctum occlusion). 11. Patinets who the investigator consider ineligible for enrolment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Corneal fluorescein staining scores | — |
Countries
Japan
Outcome results
None listed